Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trials

NCT ID: NCT02054715

Last Updated: 2021-01-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

418 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-01

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized clinical trial compares multimedia psychoeducation to print education in preparing patients with cancer for decision making about clinical trial participation. Multimedia psychoeducation includes a digital video disc (DVD) and written materials with a combined focus on knowledge and attitude change, and may be an effective method to help patients prepare for decision making about clinical trial participation. It is not yet known whether a multimedia psychoeducation is more effective than print education in preparing patients for decision making about clinical trials.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the effect of intervention assignment on patients' preparedness for decision making about clinical trial participation.

SECONDARY OBJECTIVES:

I. To determine the effect of intervention assignment on indicators of the quality of patients' decision making about clinical trial participation.

II. To examine mechanisms by which multimedia psychoeducation (MP) exerts its expected positive effects on preparedness for decision making.

TERTIARY OBJECTIVES:

I. To explore the effects of intervention assignment on clinical trial participation.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the National Cancer Institute (NCI) booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.

ARM II: Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a digital video disk (DVD) and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.

After completion of study, patients are followed up at 3-7 and 49-56 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (print educational)

Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.

Group Type EXPERIMENTAL

print educational intervention

Intervention Type BEHAVIORAL

print educational intervention

Arm II (multimedia psychoeducational)

Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.

Group Type EXPERIMENTAL

multimedia psychoeducational intervention

Intervention Type BEHAVIORAL

multimedia psychoeducational intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

print educational intervention

print educational intervention

Intervention Type BEHAVIORAL

multimedia psychoeducational intervention

multimedia psychoeducational intervention

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

intervention, educational intervention, educational

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be able to speak and read English
* Be diagnosed with cancer
* Have been informed of their eligibility for a specific phase II or III therapeutic clinical trial open for enrollment at the participating NCI Community Oncology Research Program (NCORP) site
* Have already met one or more eligibility criteria and have a reasonable expectation of meeting any remaining eligibility criteria for the therapeutic clinical trial
* Be capable of providing written informed consent for study participation

Exclusion Criteria

* Participants must not have been asked previously to participate in another therapeutic cancer clinical trial
* Participants must not have already made a decision to participate in the phase II or III therapeutic clinical trial for which they were informed of their eligibility
* Participants must not have documented or observable visual, auditory, psychiatric, or neurological disorders that would interfere with study participation (e.g., blindness, deafness, psychosis, or dementia)
* Participants must not be eligible only for phase I trial; these patients are excluded because few of these trials are offered at NCORP sites and because their design and goals differ considerably from those of phase II and III trials
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Gary Morrow

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gary Morrow

Director

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Jacobsen

Role: PRINCIPAL_INVESTIGATOR

University of Rochester

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

San Diego State University

San Diego, California, United States

Site Status

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Site Status

Hawaii MU-NCORP

Honolulu, Hawaii, United States

Site Status

Heartland NCORP

Decatur, Illinois, United States

Site Status

Kansas City Clinical Oncology Program

Prairie Village, Kansas, United States

Site Status

Gulf South MU-NCORP

New Orleans, Louisiana, United States

Site Status

Cancer Research Consortium of West Michigan

Grand Rapids, Michigan, United States

Site Status

Metro MN NCORP

Minneapolis, Minnesota, United States

Site Status

Nevada Cancer Research Foundation NCORP

Las Vegas, Nevada, United States

Site Status

Nevada NCORP

Las Vegas, Nevada, United States

Site Status

URCC / University of Rochester NCORP Research Base

Rochester, New York, United States

Site Status

Southeast Clinical Oncology Research Consortium

Winston-Salem, North Carolina, United States

Site Status

Columbus NCORP

Columbus, Ohio, United States

Site Status

Dayton Community Oncology Program

Dayton, Ohio, United States

Site Status

Geisinger Cancer Institute NCORP

Danville, Pennsylvania, United States

Site Status

Greenville Health System Cancer Instutite/Greenville NCORP

Greenville, South Carolina, United States

Site Status

Wisconsin NCORP

Marshfield, Wisconsin, United States

Site Status

Aurora NCORP

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

https://www.cancer.gov/publications/pdq

Description: Clinical trial summary from the National Cancer Institute's PDQ® database

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2013-02237

Identifier Type: REGISTRY

Identifier Source: secondary_id

URCC12107

Identifier Type: OTHER

Identifier Source: secondary_id

URCC-12107

Identifier Type: OTHER

Identifier Source: secondary_id

U10CA037420

Identifier Type: NIH

Identifier Source: secondary_id

View Link

URCC12107

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RCT of QPS vs General Information Sheet
NCT03287492 ACTIVE_NOT_RECRUITING NA